![glp-1 nejm In an earlier analysis of the SURMOUNT-1 trial, tirzepatide (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide -1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight VisualAbstract: Daily Oral GLP-1 Receptor](https://lookaside.instagram.com/seo/google_widget/crawler/?media_id=3585945231426876830)
glp-1 nejm In an earlier analysis of the SURMOUNT-1 trial, tirzepatide (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide -1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight VisualAbstract: Daily Oral GLP-1 Receptor
USD21.81
USD69.81
Pay in 4 interest-free payments of $5.45 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
![glp-1 nejm In an earlier analysis of the SURMOUNT-1 trial, tirzepatide (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide -1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight VisualAbstract: Daily Oral GLP-1 Receptor](https://www.2minutemedicine.com/wp-content/uploads/2023/09/2MM_09.10.23_2_Winnie_glp1.jpg)
![glp-1 nejm In an earlier analysis of the SURMOUNT-1 trial, tirzepatide (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide -1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight VisualAbstract: Daily Oral GLP-1 Receptor](https://www.nejm.org/cms/asset/ce1e2adf-f3d9-473d-88ac-ae012685c50e/nejmoa2028198_f1.jpg)
![glp-1 nejm In an earlier analysis of the SURMOUNT-1 trial, tirzepatide (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide -1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight VisualAbstract: Daily Oral GLP-1 Receptor](https://www.nejm.org/cms/asset/79ffe746-a9ad-4bd3-a794-0618568eb6a7/nejmc2515117_sa4t1.jpg)
![glp-1 nejm In an earlier analysis of the SURMOUNT-1 trial, tirzepatide (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide -1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight VisualAbstract: Daily Oral GLP-1 Receptor](https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-025-04124-5/MediaObjects/41591_2025_4124_Fig2_HTML.png)
:max_bytes(150000):strip_icc()/VWH-GettyImages-2126120259-c2442d334436484baa255439265b7fb1.jpg)
